Concepedia

Author

Søren C. Tamer

Novo Nordisk (Denmark)

Also Known As

Soren Can Tamer, Søren C Tamer, Søren C. Tamer, Søren Can Tamer, Søren Tamer

8

Publications

630

Citations

7

H-Index

8

Concepts

All Affiliations

Novo Nordisk (Denmark)
SC

About

Søren C. Tamer is an author at Novo Nordisk (Denmark) specializing in diabetes, metabolic syndrome, and endocrinology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

69

2

Medicine

1

1

69

3

Diabetes

1

1

69

4

Endocrinology

1

1

69

5

Body Composition

1

1

69

Søren C. Tamer

×

7

Publications

630

Citations

7

H-Index

YearCitations

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma,

The Journal of Clinical Endocrinology & Metabolism

2013

218

Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double‐blind, placebo‐controlled, phase I/II study

Mikkel Østergaard, Bo Baslund, William F. C. Rigby,

Arthritis & Rheumatism

2010

106

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: <scp>A</scp> 26‐week, randomized, controlled, <scp>P</scp>an‐<scp>A</scp>sian, treat‐to‐target trial

Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo,

Journal of Diabetes Investigation

2013

102

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion

Bruce W. Bode, Joseph Johnson, Liselotte Hyveled,

Diabetes Technology & Therapeutics

2017

72

Insulin Detemir Results in Less Weight Gain than NPH Insulin When??Used in Basal-Bolus Therapy for??Type??2 Diabetes??Mellitus, and this??Advantage Increases with Baseline??Body??Mass Index

Katarina Ra lov, Søren C. Tamer, Per Clauson,

Clinical Drug Investigation

2007

69

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: <scp>A</scp> randomized, 18‐week, open‐label, phase 3 trial (onset 3)

Helena W. Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez,

Diabetes Obesity and Metabolism

2017

44

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Stephanie Seremetis, Katarina Cepo, Josephine Skovgaard Rasmussen,

Blood

2020

19

Page 1